Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discount Price May Position Aubagio For Greater Than Expected Uptake In Multiple Sclerosis

Executive Summary

Wall Street projects modest sales for Sanofi/Genzyme’s recently approved MS drug, but by pricing it well below Gilenya and somewhat below established, widely used injectable drugs, the companies may position Aubagio for first-line use and greater than anticipated adoption by payers.

You may also be interested in...

Genzyme Must Give NICE More Data To Avoid New European Problem For Aubagio

Britain’s NICE wants more data to address uncertainties about the clinical and cost-effectiveness of Genzyme’s oral MS drug Aubagio.

Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera

The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.

Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera

The biopharma released the new name and cited a rough pricing range for multiple sclerosis drug BG-12, which has a late March PDUFA date. But management tapped the brakes a bit on analyst sales estimates, offering a few words of caution.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts